A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis

Cihan Heybeli, Andrew Bentall, Jiqiu Wen, Mariam Priya Alexander, Francis K. Buadi, Fernando G. Cosio, Patrick G. Dean, Angela Dispenzieri, David Dingli, Mireille El Ters, Morie A. Gertz, Amer Hatem, Prashant Kapoor, Hasan Khamash, Taxiarchis Kourelis, Shaji Kumar, Elizabeth C. Lorenz, Martin Mai, Eli Muchtar, David L. MurrayMikel Prieto, Carrie A. Schinstock, Mark D. Stegall, Rahma Warsame, Nelson Leung

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Longer survival using modern therapies has increased the number of patients with immunoglobulin light-chain amyloidosis receiving kidney transplantation. We evaluated 60 patients with immunoglobulin light chain amyloidosis who underwent kidney transplantation based on their hematologic response for outcomes of death, graft failure, and complications. Patient hematologic responses (light-chain in blood or urine) prior to kidney transplantation were three patients had no response, five had a partial response, six had a very good partial response, 37 had a complete response, and nine were treatment-naive patients (never treated for this disorder). After transplantation, seven of nine treatment-naive patients achieved a complete response. The median follow-up for the entire transplant cohort was 61 months. The estimated median overall survival from the time of kidney transplantation was 123 months for the entire group. Median overall survival was not reached for the very good partial response plus complete response groups, it was 47 months for no response plus partial response groups, and 117 months for the treatment-naive group (all significantly different). Median overall survival of very good partial response was 81 months, while the median was not reached in the complete response group (no significant difference). The time to amyloid recurrence was significantly longer in complete response compared to very good partial response (median 181 vs 81 months). Death-censored graft survival at one- and five-years was 98.3%, and 95.8%, respectively for all groups. Of the 60 patients, three had allograft failure, 19 died with a functioning graft, and 13 had an amyloid recurrence. Thus, outcomes after kidney transplant in patients with immunoglobulin light-chain amyloidosis seem acceptable if a very good partial response or complete response is achieved either before or after transplantation.

Original languageEnglish (US)
Pages (from-to)707-715
Number of pages9
JournalKidney international
Issue number3
StatePublished - Mar 2021


  • kidney transplantation
  • mass spectrometry
  • monoclonal gammopathy

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis'. Together they form a unique fingerprint.

Cite this